AzTrials
AzTrials

Cognitive DysfunctionMS_RehabNCT02193906

Neuropsychological Profile of a Patient's Group With Multiple Sclerosis and Effect of a Cognitive Rehabilitation Program

A study testing Cognitive training in people with Cognitive Dysfunction, run by Aveiro University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of the study is to determine the effect of an web-based intensive cognitive rehabilitation program in neuropsychological performance of a population of patients with multiple sclerosis or clinical isolated syndrome. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cognitive Dysfunction
What is being tested?
Cognitive training
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
75 participants
Where
No sites listed yet
Study dates
Dec 2012to Dec 2014
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with MS diagnosed according to McDonald criteria from 2010 and clinical isolated syndrome patients.
  • Age ≥18 years old.
  • Informed consent.

Who cannot join

  • Disease relapse in the last month.
  • Corticotherapy in the last month.
  • Expended Disability Status Scale score >6,0.

About this study

Official title: Neuropsychological Profile of a Portuguese Patient's Group With Multiple Sclerosis and Results of a Cognitive Rehabilitation Program

The purpose of the study is to determine the effect of an web-based intensive cognitive rehabilitation program in neuropsychological performance of a population of patients with multiple sclerosis or clinical isolated syndrome.

Read the detailed description

Objectives

Primary:

  1. To determine the effect of an intensive cognitive rehabilitation program in neuropsychological performance of a population of patients with multiple sclerosis or clinical isolated syndrome.

Secondary:

  1. To characterize the neuropsychological profile of a population of patients with multiple sclerosis or clinical isolated syndrome.
  2. To evaluate the relation between Expended Disability Status Scale score and cognitive dysfunction.
  3. To evaluate the impact of depression on neuropsychological performance.
  4. To evaluate the relation between cognitive dysfunction and the 9-hole peg test.
  5. To evaluate the relation between cognitive dysfunction and the 25-foot walk test.

Population and Sample Patients will be selected from an electronic database that exists in Centro Hospitalar Entre Douro e Vouga. They will be consecutively convoked and it will be proposed neuropsychological evaluation and participation in the study.

Every patient will have a baseline neuropsychological evaluation (table 1). After that, they will be randomized for training (Cogweb® program or Cogweb Monthly Notebooks®) or placebo in a 2(training):1(placebo) fashion (online program of randomization). After a 3-month period of tasks (training versus placebo), they will have another neuropsychological evaluation with the same battery used for baseline.

Patients included in intervention arm that have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb® during 3 months. Patients included in intervention arm that don't have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb Monthly Notebooks® during 3 months.

Patients included in placebo arm will have to complete a task (send an email with a copy of a journal/magazine heading) a minimum of 3 times a week.

Every patient included will have an outpatient appointment in the end of the first and second months of tasks (training versus placebo).

The placebo group is a group of patients with multiple sclerosis, selected according to inclusion and exclusion criteria, from the same database than those assigned for training.

The neuropsychological evaluation plan comprises: global efficiency (Montreal Cognitive Assessment test); processing speed (reading task of Stroop test, symbol searching from Wechsler Adult Intelligence Scale); attention (letter cut of Behavioural Inattention Test, Trail making test part B); memory (Letter and number sequence of Wechsler Memory Scale, digit memory, spatial localization of Wechsler Memory Scale, logic memory of Wechsler Memory Scale, word list from Wechsler Memory Scale); executive functions (colour naming task of Stroop test, inhibition from INECO frontal screening, verbal initiative from Lisbon Dementia Evaluating Battery, Zoo Map from Ineco, Matrix from Wechsler Adult Intelligence Scale) and anxious and depressive symptoms (Hospital Anxiety and Depression Scale).

Sample Size There will be convoked 75 patients (convenience sample).

Design Experimental, single-center study.

Clinical Practice Concomitant medication allowed Any except corticotherapy. Discontinuation criteria

  1. Desire of the patient to end participation in the study.
  2. Noncompliance of the intervention plan or fail the appointments predetermined.

Parameters to evaluate de study objectives

  1. Neuropsychological battery: performed at baseline and at 3 months after the completion of study tasks (each test is composed of numerical, continuous variables).
  2. Expended Disability Status Scale score: screening at baseline.
  3. Stage of the disease: screening from the database.
  4. Number of years of disease evolution.
  5. 9-hole peg test: performed at baseline and at 3 months after the completion of study tasks.
  6. 25-foot walk test: performed at baseline and at 3 months after the completion of study tasks.

Efficacy Endpoints Primary: To determine if an intensive cognitive rehabilitation program changes, in a statistically significant way, the performance on a neuropsychological evaluation after 3 months of training, comparing to the control group (number of tests scored more than one standard deviation from the normal value). There will be analyzed the total and partial scores for each test. The individuals with cognitive deficits at baseline will be analyzes as rehabilitation group. The others (without cognitive deficits in cognitive evaluation at baseline) will be analyzed as a separated group of cognitive stimulation.

Secondary:

  1. To characterize the profile of a population of patients with multiple sclerosis, according to the performance in a neuropsychological battery, in terms of processing speed, attention, memory and executive functions.
  2. To determine the percentage of patients with Cognitive Dysfunction, defined as performance >1standard deviation below the median in ≥3 tests of the battery.
  3. To correlate the Expended Disability Status Scale score with the Cognitive Dysfunction.
  4. To correlate the Hospital Anxiety and Depression Scale score with the Cognitive Dysfunction.
  5. To correlate the 9-hole peg test with the Cognitive Dysfunction.
  6. To correlate the 25-foot walk test with the Cognitive Dysfunction.

Safety Endpoints Not applicable.

Being tested
Cognitive training, Placebo task
Keywords
Cognitive training, Multiple sclerosis, Cognitive deficits
Medical subject headings
Cognitive Dysfunction, Multiple Sclerosis, Cognition Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cognitive trainingOther

    Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients who have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb® during 3 months. Patients who don't have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb Monthly Notebooks® during 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.

  • Placebo taskOther

    Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients will have to complete a placebo task (send an email with a copy of a journal/magazine heading) a minimum of 3 times a week, for 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.

Study groups in NCT02193906
Study groupRoleWhat they receive
Intervention groupExperimentalCognitive training.
Receives: Other: Cognitive training
Placebo groupPlacebo comparatorPlacebo task.
Receives: Other: Placebo task

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Effect of an intensive cognitive rehabilitation program in neuropsychological performance of a population of patients with multiple sclerosis or clinical isolated syndrome.

    Two neuropsychological assessments were made: at baseline and at 3 months with the same neuropsychological battery to all the patients.

    After that, the statistically significant differences between the two study groups (comparing the standard deviations from the normative values of each test), will be accessed. The tests will be analysed separately and globally as a battery.

    Measured: 3 months

Secondary outcomes (6)
  1. Neuropsychological profile of a population of patients with multiple sclerosis or clinical isolated syndrome.

    Characterization of the cognitive profile of deficits in the following domains (percentage of deficits by domain, considering all patients who have done the baseline evaluation): global efficiency, processing speed, attention, memory and executive functions.

    Measured: Baseline

  2. Percentage of patients with Cognitive Dysfunction

    Patients with performance >1standard deviation below the median in ≥3 tests of the battery of neuropsychological evaluation will be considered as having Cognitive Dysfunction.

    Measured: Baseline

  3. Relation between Expended Disability Status Scale score and cognitive dysfunction.

    Patients with performance >1standard deviation below the median in ≥3 tests of the battery of neuropsychological evaluation will be considered as having Cognitive Dysfunction.

    Correlation between Expended Disability Status Scale score and Cognitive Dysfunction.

    Measured: Baseline

  4. Impact of depression on neuropsychological performance.

    Patients with performance >1standard deviation below the median in ≥3 tests of the battery of neuropsychological evaluation will be considered as having Cognitive Dysfunction.

    Correlation between Hospital Anxiety and Depression Scale score and Cognitive Dysfunction.

    Measured: Baseline

  5. Relation between cognitive dysfunction and the 9-hole peg test.

    Patients with performance >1standard deviation below the median in ≥3 tests of the battery of neuropsychological evaluation will be considered as having Cognitive Dysfunction.

    Correlation between 9-hole peg test time frame (in seconds) and Cognitive Dysfunction.

    Measured: Baseline

  6. Relation between cognitive dysfunction and the 25-foot walk test.

    Patients with performance >1standard deviation below the median in ≥3 tests of the battery of neuropsychological evaluation will be considered as having Cognitive Dysfunction.

    Correlation between 25-foot walk test time frame (in seconds) and Cognitive Dysfunction.

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jul 2014 (estimated)
  2. Study startDec 2012
  3. Primary completionJun 2013
  4. Study completionDec 2014 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
75 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02193906
Sponsor's protocol ID
MSR-2013
Acronym
MS_Rehab
Status last verified
Jul 2014
First submitted
18 Sep 2013
Last updated
18 Jul 2014
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Cognitive training in people with Cognitive Dysfunction, run by Aveiro University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Jul 2014. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Effect of an intensive cognitive rehabilitation program in neuropsychological performance of a population of patients with multiple sclerosis or clinical isolated syndrome. (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jul 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in